Ruihuan Chen

Dr. Ruihuan Chen

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2006 in Cancer Cell
Verified
Journal Article
Closed access
HPHeidi S. Phillips
Heidi S. Phillips
SKSamir Kharbanda
Samir Kharbanda
RCRuihuan Chen
Ruihuan Chen
WFWilliam F. Forrest
William F. Forrest
RSRobert H. Soriano
Robert H. Soriano
KAKen Aldape
Ken Aldape

1 April 2010 in Cancer Cell
Verified
Journal Article
Closed access
RCRuihuan Chen
Ruihuan Chen
MNMerry C. Nishimura
Merry C. Nishimura
SBStephanie M. Bumbaca
Stephanie M. Bumbaca
SKSamir Kharbanda
Samir Kharbanda
WFWilliam F. Forrest
William F. Forrest
HPHeidi S. Phillips
Heidi S. Phillips

31 October 2012 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
SLSichen Li
Sichen Li
ACArthur P. Chou
Arthur P. Chou
WCWeidong Chen
Weidong Chen
RCRuihuan Chen
Ruihuan Chen
YDYuzhong Deng
Yuzhong Deng
ALAlbert Lai
Albert Lai
Mutations in isocitrate dehydrogenase 1 (IDH1) or 2 (IDH2) are found in a subset of gliomas. Among the many phenotypic differences between mutant and wild-type IDH1/2 gliomas, the most salient is that IDH1/2 mutant glioma patients demonstrate markedly improved survival compared with IDH1/2 wild-type glioma patients. To address the mechanism underlying the superior clinical outcome of IDH1/2 mutant glioma patients, we investigated whether overexpression of the IDH1R132H protein could affect response to therapy in the context of an isogenic glioma cell background. Stable clonal U87MG and U373MG cell lines overexpressing IDH1WT and IDH1R132H were generated, as well as U87MG cell lines overexpressing IDH2WT and IDH2R172K. In vitro experiments were conducted to characterize baseline growth and migration and response to radiation and temozolomide. In addition, reactive oxygen species (ROS) levels were measured under various conditions. U87MG-IDH1R132H cells, U373MG-IDH1R132H cells, and U87MG-IDH2R172K cells demonstrated increased sensitivity to radiation but not to temozolomide. Radiosensitization of U87MG-IDH1R132H cells was accompanied by increased apoptosis and accentuated ROS generation, and this effect was abrogated by the presence of the ROS scavenger N-acetyl-cysteine. Interestingly, U87MG-IDH1R132H cells also displayed decreased growth at higher cell density and in soft agar, as well as decreased migration. Overexpression of IDH1R132H and IDH2R172K mutant protein in glioblastoma cells resulted in increased radiation sensitivity and altered ROS metabolism and suppression of growth and migration in vitro. These findings provide insight into possible mechanisms contributing to the improved outcomes observed in patients with IDH1/2 mutant gliomas.

1 March 1996 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
BDBruno Doiron
Bruno Doiron
MCMarie-Hélène Cuif
Marie-Hélène Cuif
RCRuihuan Chen
Ruihuan Chen
AKAxel Kahn
Axel Kahn
Glucose catabolism induces the expression of the L-type pyruvate kinase (L-PK) gene through the glucose response element (GIRE). The metabolic pathway used by glucose after its phosphorylation to glucose 6-phosphate by glucokinase to induce L-PK gene expression in hepatocytes remains unknown. The sugar alcohol xylitol is metabolized to xylulose 5-phosphate, an intermediate of the nonoxidative branch of the pentose phosphate pathway. In this study, we demonstrated that xylitol at low concentration (O.5 mM) induced the expression of the L-PK/CAT construct in glucose-responsive mhAT3F hepatoma cells at the same level as 20 mM glucose, while it did not affect intracellular concentration of glucose 6-phosphate significantly. The effect of xylitol on the induction of the L-PK gene expression was noncumulative with that of glucose since 20 mM glucose plus 5 mM xylitol induced the expression of the L-PK/CAT construct similarly to 20 mM glucose alone. In hepatocytes in primary culture, 5 mM xylitol induced accumulation of the L-PK mRNA even in the absence of insulin. Furthermore, the response to xylitol as well as glucose required the presence of a functional GIRE. It can be assumed from these results that glucose induces the expression of the L-PK gene through the nonoxidative branch of the pentose phosphate pathway. The effect of xylitol at low concentration suggests that the glucose signal to the transcriptional machinery is mediated by xylulose 5-phosphate.

27 February 2007 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
LSLiliana Soroceanu
Liliana Soroceanu
SKSamir Kharbanda
Samir Kharbanda
RCRuihuan Chen
Ruihuan Chen
RSRobert H. Soriano
Robert H. Soriano
KAKen Aldape
Ken Aldape
HPHeidi S. Phillips
Heidi S. Phillips
Amplification or overexpression of growth factor receptors is a frequent occurrence in malignant gliomas. Using both expression profiling and in situ hybridization, we identified insulin-like growth factor 2 (IGF2) as a marker for a subset of glioblastomas (GBMs) that lack amplification or overexpression of EGF receptor. Among 165 primary high-grade astrocytomas, 13% of grade IV tumors and 2% of grade III tumors expressed IGF2 mRNA levels >50-fold the sample population median. IGF2-overexpressing tumors frequently displayed PTEN loss, were highly proliferative, exhibited strong staining for phospho-Akt, and belonged to a subclass of GBMs characterized by poor survival. Using a serum-free culture system, we discovered that IGF2 can substitute for EGF to support the growth of GBM-derived neurospheres. The growth-promoting effects of IGF2 were mediated by the insulin-like growth factor receptor 1 and phosphoinositide-3-kinase regulatory subunit 3 (PIK3R3), a regulatory subunit of phosphoinositide 3-kinase that shows genomic gains in some highly proliferative GBM cases. PIK3R3 knockdown inhibited IGF2-induced growth of GBM-derived neurospheres. The current results provide evidence that the IGF2–PIK3R3 signaling axis is involved in promoting the growth of a subclass of highly aggressive human GBMs that lack EGF receptor amplification. Our data underscore the importance of the phosphoinositide 3-kinase/Akt pathway for growth of high-grade gliomas and suggest that multiple molecular alterations that activate this signaling cascade may promote tumorigenesis. Further, these findings highlight the parallels between growth factors or receptors that are overexpressed in GBMs and those that support in vitro growth of tumor-derived stem-like cells.

1 April 2001 in Molecular Therapy
Verified
Journal Article
Open access
PDF file
RCRuihuan Chen
Ruihuan Chen
MMMarcia L. Meseck
Marcia L. Meseck
SWSavio L.C. Woo
Savio L.C. Woo
Paradigms of insulin gene therapy for type 1 diabetes should incorporate vigorous control for insulin gene expression to be effective in correcting postprandial hyperglycemia and to be safe in preventing fasting hypoglycemia. We hypothesize that hepatic insulin gene expression auto-regulated positively by glucose and negatively by insulin might be both effective and safe in the treatment of type 1 diabetes. Expression of the glucose 6-phosphatase (G6Pase) gene in the liver is both stimulated by glucose and suppressed by insulin. The G6Pase promoter incorporated with intronic enhancers of the aldolase B gene was used to direct insulin gene expression in the liver of streptozotocin-induced diabetic nude rats. In the treated animals, blood insulin levels were elevated after feeding, and nonfasting hyperglycemia was significantly reduced. Glucose tolerance testing also illustrated that the treated animals exhibited accelerated glucose utilization rates. Upon fasting, blood glucose was reduced to normoglycemic range within 4 h and maintained at that level during the prolonged fasting of 16 h. No hypoglycemia was observed in any treated animals at any time throughout the fasting period, as blood insulin gradually declined to the normal range. These results suggest that auto-regulated hepatic insulin expression can potentially be developed as an effective and safe treatment modality for type 1 diabetes.